BG103674A - Polymorphous form of zopolrestatmonohydrate - Google Patents

Polymorphous form of zopolrestatmonohydrate

Info

Publication number: BG103674A
Authority: BG; Bulgaria
Prior art keywords: zopolrestatmonohydrate; methods; relates; forms; polymorphous form
Prior art date: 1998-08-21

Application number

BG103674A

Other languages

Bulgarian (bg)

English (en)

Inventor

John Lambert

Timothy Norris

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-21

Filing date

1999-08-20

Publication date

2000-03-31

1999-08-20 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2000-03-31 Publication of BG103674A publication Critical patent/BG103674A/xx

Links

239000000203 mixture Substances 0.000 abstract 2
BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
208000002249 Diabetes Complications Diseases 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
229940116269 uric acid Drugs 0.000 abstract 1
-1 uric acid lipid Chemical class 0.000 abstract 1
229950005346 zopolrestat Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

BG103674A 1998-08-21 1999-08-20 Polymorphous form of zopolrestatmonohydrate BG103674A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9747498P	1998-08-21	1998-08-21

Publications (1)

Publication Number	Publication Date
BG103674A true BG103674A (en)	2000-03-31

Family

ID=22263562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103674A BG103674A (en)	1998-08-21	1999-08-20	Polymorphous form of zopolrestatmonohydrate

Country Status (31)

Country	Link
US (1)	US6159976A (fr)
EP (1)	EP0982306A3 (fr)
JP (1)	JP2000072769A (fr)
KR (1)	KR20000017411A (fr)
CN (1)	CN1245804A (fr)
AP (1)	AP9901662A0 (fr)
AU (1)	AU4453299A (fr)
BG (1)	BG103674A (fr)
BR (1)	BR9903873A (fr)
CA (1)	CA2280590A1 (fr)
EA (1)	EA199900675A3 (fr)
EE (1)	EE9900385A (fr)
GT (1)	GT199900137A (fr)
HR (1)	HRP990259A2 (fr)
HU (1)	HUP9902783A3 (fr)
ID (1)	ID23307A (fr)
IL (1)	IL131419A0 (fr)
IS (1)	IS5155A (fr)
MA (1)	MA26678A1 (fr)
NO (1)	NO994027L (fr)
NZ (1)	NZ337363A (fr)
OA (1)	OA11150A (fr)
PA (1)	PA8480601A1 (fr)
PE (1)	PE20000993A1 (fr)
PL (1)	PL335016A1 (fr)
SG (1)	SG83147A1 (fr)
TN (1)	TNSN99159A1 (fr)
TR (1)	TR199901996A2 (fr)
UY (1)	UY25668A1 (fr)
YU (1)	YU39899A (fr)
ZA (1)	ZA995297B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20221430T1 (hr)	2010-07-16	2023-01-06	The Trustees Of Columbia University In The City Of New York	Inhibitori aldozoreduktaze i njihova uporaba
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
WO2014126885A1 (fr) *	2013-02-13	2014-08-21	Mylari Banavara L	Sels solubles dans l'eau d'inhibiteurs d'aldose réductase pour le traitement de complications diabétiques
RS61239B1 (sr)	2016-06-21	2021-01-29	Univ Columbia	Inhibitori aldozne reduktaze i postupci korišćenja
IL272246B2 (en)	2017-07-28	2026-01-01	Applied Therapeutics Inc	History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (fr)	2019-04-01	2020-10-08	Andrew Wasmuth	Inhibiteurs de l'aldose reductase
JP2022531466A (ja)	2019-05-07	2022-07-06	ユニバーシティオブマイアミ	遺伝性ニューロパチーおよび関連障害の処置および検出
EP4125909A1 (fr)	2020-03-31	2023-02-08	Applied Therapeutics Inc.	Inhibiteurs d'aldose réductase pour le traitement du syndrome de détresse respiratoire aiguë, d'une inflammation/lésion pulmonaire aiguë, d'une lésion cardiaque et pour une thérapie antivirale
WO2021222165A1 (fr)	2020-05-01	2021-11-04	Applied Therapeutics, Inc.	Inhibiteurs d'aldose réductase pour le traitement d'une déficience en sorbitol déshydrogénase
US20230322786A1 (en) *	2020-09-08	2023-10-12	Teva Pharmaceuticals International Gmbh	Solid state forms of at-001 and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4748280A (en) *	1985-11-07	1988-05-31	Pfizer Inc.	Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) *	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
JPH0676391B2 (ja) *	1987-06-09	1994-09-28	フアイザー・インコーポレイテツド	ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) *	1987-06-09	1989-09-19	Pfizer Inc.	Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) *	1988-02-29	1990-02-27	Pfizer Inc.	Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) *	1989-05-11	1990-09-04	Pfizer Inc.	Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (fr) *	1990-08-28	1992-03-05	Pfizer Inc.	Monohydrate d'acide 3-(5-trifluoromethylbenzothiazol-2-ylmethyle)-4-oxo-3h-phytalazine-1-ylacetique
US5391551A (en) *	1993-05-10	1995-02-21	Pfizer Inc.	Method of lowering blood lipid levels
IL120264A0 (en) *	1996-02-29	1997-06-10	Pfizer	Method of reducing tissue damage associated with non-cardiac ischemia

1999
- 1999-08-06 EP EP99306252A patent/EP0982306A3/fr not_active Withdrawn
- 1999-08-13 US US09/374,729 patent/US6159976A/en not_active Expired - Fee Related
- 1999-08-16 IL IL13141999A patent/IL131419A0/xx unknown
- 1999-08-17 IS IS5155A patent/IS5155A/is unknown
- 1999-08-17 AU AU44532/99A patent/AU4453299A/en not_active Abandoned
- 1999-08-18 TN TNTNSN99159A patent/TNSN99159A1/fr unknown
- 1999-08-18 MA MA25738A patent/MA26678A1/fr unknown
- 1999-08-19 UY UY25668A patent/UY25668A1/es not_active Application Discontinuation
- 1999-08-19 SG SG9904131A patent/SG83147A1/en unknown
- 1999-08-19 YU YU39899A patent/YU39899A/sh unknown
- 1999-08-19 HU HU9902783A patent/HUP9902783A3/hu unknown
- 1999-08-19 GT GT199900137A patent/GT199900137A/es unknown
- 1999-08-19 ZA ZA9905297A patent/ZA995297B/xx unknown
- 1999-08-19 EE EEP199900385A patent/EE9900385A/xx unknown
- 1999-08-19 CA CA002280590A patent/CA2280590A1/fr not_active Abandoned
- 1999-08-19 AP APAP/P/1999/001662A patent/AP9901662A0/en unknown
- 1999-08-19 OA OA9900185A patent/OA11150A/en unknown
- 1999-08-20 BG BG103674A patent/BG103674A/xx unknown
- 1999-08-20 PE PE1999000844A patent/PE20000993A1/es not_active Application Discontinuation
- 1999-08-20 BR BR9903873-0A patent/BR9903873A/pt not_active Application Discontinuation
- 1999-08-20 TR TR1999/01996A patent/TR199901996A2/xx unknown
- 1999-08-20 ID IDP990796A patent/ID23307A/id unknown
- 1999-08-20 HR HR990259A patent/HRP990259A2/hr not_active Application Discontinuation
- 1999-08-20 PL PL99335016A patent/PL335016A1/xx not_active Application Discontinuation
- 1999-08-20 EA EA199900675A patent/EA199900675A3/ru unknown
- 1999-08-20 PA PA19998480601A patent/PA8480601A1/es unknown
- 1999-08-20 KR KR1019990034527A patent/KR20000017411A/ko not_active Ceased
- 1999-08-20 NZ NZ337363A patent/NZ337363A/xx unknown
- 1999-08-20 NO NO994027A patent/NO994027L/no not_active Application Discontinuation
- 1999-08-23 JP JP11235855A patent/JP2000072769A/ja active Pending
- 1999-08-23 CN CN99118068A patent/CN1245804A/zh active Pending

Also Published As

Publication number	Publication date
YU39899A (sh)	2002-12-10
EP0982306A3 (fr)	2000-07-05
US6159976A (en)	2000-12-12
EA199900675A2 (ru)	2000-02-28
ZA995297B (en)	2001-02-19
PA8480601A1 (es)	2000-09-29
AU4453299A (en)	2000-03-09
NZ337363A (en)	2001-01-26
NO994027L (no)	2000-02-22
SG83147A1 (en)	2001-09-18
EP0982306A2 (fr)	2000-03-01
HUP9902783A2 (hu)	2000-12-28
AP9901662A0 (en)	1999-09-30
CA2280590A1 (fr)	2000-02-21
BR9903873A (pt)	2000-09-19
MA26678A1 (fr)	2004-12-20
PE20000993A1 (es)	2000-10-04
NO994027D0 (no)	1999-08-20
HUP9902783A3 (en)	2001-01-29
ID23307A (id)	2000-04-05
HU9902783D0 (en)	1999-10-28
TNSN99159A1 (fr)	2005-11-10
IS5155A (is)	2000-02-22
EA199900675A3 (ru)	2000-06-26
TR199901996A2 (xx)	2000-03-21
EE9900385A (et)	2000-04-17
UY25668A1 (es)	2001-08-27
CN1245804A (zh)	2000-03-01
GT199900137A (es)	2001-02-09
PL335016A1 (en)	2000-02-28
HRP990259A2 (en)	2000-06-30
JP2000072769A (ja)	2000-03-07
IL131419A0 (en)	2001-01-28
OA11150A (en)	2003-04-16
KR20000017411A (ko)	2000-03-25

Publication	Publication Date	Title
CA2331395A1 (fr)	1999-11-18	Nouveaux analogues d'acides gras destines au traitement du diabete
WO2002014252A3 (fr)	2002-09-12	Compositions contenant des stilbenoides hypoglycemiquement actifs
FI962799A0 (fi)	1996-07-09	Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
WO2002013811A3 (fr)	2002-08-15	Compositions contenant des stilbenoides hypoglycemiants
WO2003000200A3 (fr)	2004-09-02	ss-2'-OU 3'-HALONUCLEOSIDES
BR0110084A (pt)	2002-12-31	Composições e métodos para melhorar saúde vascular
MXPA02011632A (es)	2004-05-05	Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
BE2015C026I2 (en)	2018-08-24	2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
MXPA04004842A (es)	2004-08-02	Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es)	2004-08-02	Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en)	2004-08-31	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CR6540A (es)	2008-09-17	Trifluorobutenos nematicidas
DK0695171T3 (da)	1997-06-02	Lyosfærer indeholdende gonadotropin
BG103674A (en)	2000-03-31	Polymorphous form of zopolrestatmonohydrate
ATE188869T1 (de)	2000-02-15	Stabilisiertes sonnenschutzmittel
WO2001063410A3 (fr)	2002-07-25	Systeme et procede de mise en oeuvre d'un mecanisme de projet
EP1156058A3 (fr)	2005-06-08	Procédé de préparation de (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione et analogues
MXPA02007903A (es)	2004-09-10	Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
WO2004050123A3 (fr)	2004-07-29	Composition de valdecoxibe liquide concentre
EP1121932A4 (fr)	2001-12-19	Medicaments pour maladies oculaires
WO1999058098A8 (fr)	2000-02-24	Antithrombines iii humaines et procedes connexes
WO2001051489A3 (fr)	2001-12-27	Procedes pour abaisser les niveaux d'acide urique
WO2000015797A3 (fr)	2000-08-24	Compositions et methodes de traitement des maladies relatives au syteme immunitaire
DE69926223D1 (de)	2005-08-25	Verfahren zur herstellung von zwischenprodukten
AU3868895A (en)	1996-05-15	Process for the preparation of furosemide